Document:

acad-ex101_114.htm

 

Exhibit 10.1

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

 

MSA Attachment No. 7

 

This MSA Attachment (MSA Attachment) is entered into between Siegfried AG, Untere Bruehlstrasse 4, 4800 Zofingen, Switzerland (Siegfried) and ACADIA Pharmaceuticals GmbH, c/o KENDRIS AG, Seidenhofstrasse 14, 6003 Luzern, Switzerland (ACADIA) under the Master Services Agreement dated December 15, 2016 (the Agreement). Pursuant to the Agreement, Siegfried has agreed to perform certain Services in accordance with written MSA Attachments, such as this one, entered into from time to time. Capitalized terms used in this MSA Attachment and not otherwise defined have the meanings given to them in the Agreement.

 

The Parties hereby agree as follows:

	
1.
	
MSA Attachment

This document constitutes a MSA Attachment under the Agreement and this MSA Attachment No.7 and the Services contemplated herein are development Services subject to the terms and provisions of the Agreement. Except if expressly modified in this MSA Attachment No.7, the terms of the Agreement are hereby incorporated by reference herein. 

 

	
2.
	
Services, Product, and Materials

	
 
	
2.1.
	
Scope of Work 

 

1st  Objective, Process Transfer of the [***] process from Siegfried Zofingen (“Zofingen”) site to Siegfried Evionnaz  (“Evionnaz”) site

 

[***]

 

Process Transfer Approach:

 

[***]

2nd Objective, Validation Campaign

	
•
	
Manufacture of validation campaign [***] 

	
•
	
Shipment by [***].

 

3rd Objective, Stability Study (Validation Batches)

	
•
	
[***] batches of API will be held under the following conditions:

[***]

 

	
 
	
2.2.
	
Key Milestone Summary and Delivery

 

See section 3 table Milestones and Deliverables.

	
 
	
2.3.
	
Deliverables 

 

Zofingen deliverables to Evionnaz

	
 
	
•
	
R&D: 

[***]

 

 

	
 
	
•
	
SHE Reports:

[***]

	
 
	
•
	
Production:

[***]

	
 
	
•
	
Analytics:

	
 
	
•
	
[***]

	
 
	
•
	
Quality Assurance:

[***]

 

ACADIA deliverables to Evionnaz

	
 
	
•
	
ACADIA will provide 

[***]

 

Siegfried deliverables to ACADIA

[***]

 

	
 
	
2.4.
	
Project Assumptions

 

	
 
	
•
	
Process Transfer

[***]

 

	
 
	
•
	
Analytical Transfer assumptions and scope

[***]

 

Quality Activities Assumptions and Scope

[***]

 

Validation Campaign 

[***]

 

	
 
	
2.5.
	
Schedule:

[***]

 

	
 
	
2.6.
	
Out of Scope

[***]

 

	
3.
	
Commercial Terms

[***]

 

Siegfried AG

 

	
/s/ Dr. Marcel Signer
	
 
	
/s/ Dr. Luca Parlanti

	
Name:
	
Dr. Marcel Singer
	
 
	
Name:
	
Dr. Luca Parlanti

	
Function: Site Manager
	
 
	
Function: Head of Exclusive Sales

	
 
	
 
	
 
	
Drug Substance

 

ACADIA Pharmaceuticals GmbH

 

	
/s/ Austin Kim
	
 

	
Name:  Austin Kim
	
 

	
 
	
 

	
Function:  Director
	
 

 

 

 

Attachment 1

Table of Analytical Methods

[***]

 

 

 

Attachment 2 – Specification for Pimavanserin Tartate

[***]Document

Exhibit 10.4

SEVENTH AMENDMENT TO THE
PENN NATIONAL GAMING, INC. 
DEFERRED COMPENSATION PLAN

WHEREAS, Penn National Gaming, Inc. (the “Company”) maintains the Penn National Gaming, Inc. Deferred Compensation Plan (the “Plan”); and

WHEREAS, Section 12.2 of the Plan provides that the CEO may adopt administrative amendments to the Plan; and

WHEREAS, the Company wishes to amend the Plan to resume annual Company contributions thereto effective as of October 1, 2020;

NOW, THEREFORE, the Plan is hereby amended, effective as of October 1, 2020, as follows:

1.Section 3.5 is amended by adding the following after the second sentence therein: 

“Effective October 1, 2020, amounts shall be credited to the Company Contribution Account of any Participant pursuant to the first sentence of this paragraph with respect to any compensation received by a Participant on or after October 1, 2020.”

2.In all other respects, the Plan shall remain as previously written. 

IN WITNESS WHEREOF, this Seventh Amendment has been adopted this 29 day of September, 2020.

									
	ATTEST:		JAY A. SNOWDEN
			CHIEF EXECUTIVE OFFICER
			
	/s/ Lori A. Heyer		/s/ Jay A. Snowdenrgnx-ex101_116.htm

EXHIBIT 10.1

REGENXBIO INC.

COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS

(as adopted by the Board of Directors on September 22, 2015 and amended on October 29, 2020)

	
A.
	
Cash Compensation 

	
 
	
1.
	
Board retainer: $40,000 per year for each non-employee director, paid in quarterly installments in arrears.

	
 
	
2.
	
Chairman of the Board retainer: $30,000 per year, paid in quarterly installments in arrears.

	
 
	
3.
	
Lead Independent Director retainer: $25,000 per year, paid in quarterly installments in arrears.

	
 
	
4.
	
Committee chair retainer: $18,000 per year for the Audit Committee chair, $15,000 per year for the Compensation Committee chair, and $8,500 per year for the Nominating and Corporate Governance Committee chair, paid in quarterly installments in arrears.

	
 
	
5.
	
Committee member retainer: $9,000 per year for each non-chair member of the Audit Committee, $6,000 per year for each non-chair member of the Compensation Committee, and $5,000 per year for each non-chair member of the Nominating and Corporate Governance Committee, paid in quarterly installments in arrears.

	
B.
	
Equity Compensation 

	
 
	
1.
	
Initial stock option grant: stock option for each non-employee director to purchase 20,000 shares of REGENXBIO Inc. (the “Company”) common stock.  The per share price of each option shall equal 100% of the Fair Market Value (as defined in the 2015 Equity Incentive Plan (the “EIP”)) of a share of common stock of the Company on the date the option is granted.  The option shall vest in equal monthly installments over the 36 months following the grant date, with immediate full vesting in the event of a Change in Control (as defined in the EIP).  The option will be granted by the Compensation Committee under the EIP in conjunction with the director’s initial appointment or election to the Board.

	
 
	
2.
	
Annual stock option grant: stock option for each non-employee director to purchase 10,000 shares of the Company’s common stock.  The per share price of each option shall equal 100% of the Fair Market Value of a share of common stock of the Company on the date the option is granted.  The option shall vest in equal monthly installments over the 12 months following the grant date, with immediate full vesting in the event of a Change in Control. The option will be 

1

 

	
 
		
granted by the Compensation Committee under the EIP following the election of such director at the Company’s annual meeting of stockholders.

	
C.
	
Other Items

	
 
	
1.
	
Non-employee directors will be reimbursed for reasonable out-of-pocket expenses incurred to attend Board and Committee meetings.

	
 
	
2.
	
Customary director and officer insurance is provided for non-employee directors.

2rgnx-ex102_114.htm

EXHIBIT 10.2

Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks.

UNIVERSITY of PENNSYLVANIA

Fifth Amendment to License Agreement

 

This Fifth Amendment to License Agreement (this “Fifth Amendment”) effective as of September 11, 2020 (this “Fifth Amendment Effective Date”), is made by and between The Trustees of the University of Pennsylvania (“Penn”) and REGENXBIO Inc. (“Company”) (collectively, the “Parties”) and amends the License Agreement between the Parties, which was effective as of February 24, 2009, as subsequently amended by a First Amendment dated March 6, 2009, a Second Amendment dated September 9, 2014, a Third Amendment dated April 29, 2016, and a Fourth Amendment dated April 4, 2019 (the “License Agreement”). All capitalized terms used but not defined herein shall have the meaning set forth in the License Agreement.

 

BACKGROUND

 

WHEREAS, the Parties desire to amend the License Agreement to clarify the division of recoveries in infringement litigation, to correct a scrivener’s error in Section 8.5 and to update payment and notice addresses;

 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the Parties, intending to be bound, hereby mutually agree to the following:

 

 

	
 
	
1.
	
Section 8.5 of the License Agreement is hereby amended and restated in its entirety:

 

“8.5Recoveries from Litigation. Except as expressly provided in this Section 8.5 or as otherwise agreed between the parties, if Company prosecutes any infringement claims, Company will use the financial recoveries from such claims, if any, (a) first, to reimburse [****] for its litigation expenditures; and (b) second, to retain any remainder but to treat the remainder as [****] for the purpose of determining [****]. If Company prosecutes any infringement claims with Penn joined as a voluntary party, unless otherwise agreed between the parties, then Company will use the financial recoveries from such claims, if any, (a) first, to reimburse [****] and [****] for their respective litigation expenditures on a dollar-for-dollar basis; and (b) second, to retain any remainder but to [****]. If Penn prosecutes any infringement claims independent of [****], then Penn will prosecute such infringement at [****] expense and will retain any financial recoveries [****].”

 

	
 
	
2.
	
For clarity, there are no sections 3.6 or 3.7 in the License Agreement.

 

	
 
	
3.
	
Section 4.6 of the License Agreement is hereby amended and restated in its entirety and replaced by the following:
	
 

 

 

“4.6Place of Payment. All payments by Company to Penn hereunder shall be made by deposit of USD in the requisite amount to the “The Trustees of the University of Pennsylvania” and will be made by delivery to any one of the following:

 

		
	
By ACH/Wire:
	
By Check (lockbox):

	
Wells Fargo Bank, N.A.
	
The Trustees of the

	
ABA #[****] (domestic wires)
	
University of Pennsylvania

	
SWIFT CODE: [****]
	
c/o Penn Center for Innovation

	
(international wires only)
	
PO Box 785546

	
Account Number: [****]
	
Philadelphia, PA 19178-5546

	
Payment should include the necessary amount to cover any

bank charges incurred.
	
 

 

	
 
	
4.
	
The Notice Addresses of the parties under 13.6 of the License Agreement are hereby updated by the Notice Addresses listed on the Signature Page.
	
 

 

	
 
	
5.
	
This Fifth Amendment amends the terms of the License Agreement and is deemed incorporated into, and governed by all other terms of, the License Agreement. To the extent that the License Agreement is explicitly amended by this Fifth Amendment, the terms of this Fifth Amendment will control where the terms of the License Agreement are contrary to or conflict with the terms of this Fifth Amendment. All other terms and conditions of the License Agreement not explicitly amended by this Fifth Amendment shall remain in full force and effect. The License Agreement, as previously amended, shall, together with this Fifth Amendment, be read and construed as a single instrument.
	
 

 

	
 
	
6.
	
Signatures on this Fifth Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail transmission, which signatures shall be deemed originals. If executed in counterparts, the Fifth Amendment shall be effective as if simultaneously executed.
	
 

 

[Intentionally left blank]

 

2

 
 

 

 

 

IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Fifth Amendment to be executed by their duly authorized representatives.

 

 

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

 

By:  /s/ John S. Swartley

Name: John S. Swartley, PhD

Title: Associate Vice Provost for Research and Executive Director, PCI

Date:  September 11, 2020

REGENXBIO INC.

 

By: /s/ Kenneth T. Mills 

Name: Kenneth T. Mills

Title: President and CEO

Date:  9/11/20

 

 

 

 

Address:Address:

Penn Center for Innovation9600 Blackwell Road

University of PennsylvaniaSuite 210

3600 Civic Center Blvd.,Rockville, MD 20850

9th FloorAttention: CEO

Philadelphia, PA 19104-4310 Attention: Managing Director

 

Required copy to:

University of Pennsylvania9600 Blackwell Road

Office of General CounselSuite 210

2929 Walnut Street, Suite 400Rockville, MD 20850

Philadelphia, PA 19104-5509Attention: Chief Legal Officer Attention: General Counsel

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]